MARKET

DCTH

DCTH

Delcath Sys
NASDAQ
2.900
+0.010
+0.35%
Closed 16:00 12/07 EST
OPEN
2.890
PREV CLOSE
2.890
HIGH
2.900
LOW
2.880
VOLUME
7.25K
TURNOVER
10.42K
52 WEEK HIGH
9.00
52 WEEK LOW
2.340
MARKET CAP
24.93M
P/E (TTM)
-0.7656
1D
5D
1M
3M
1Y
5Y
Delcath Systems's Return On Capital Employed Overview
Benzinga · 1d ago
Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced the publication of a retrospective analysis of patients who underwent a percutaneous hepatic perfusi...
PR Newswire · 2d ago
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. (Nasdaq: DCTH), announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to employment to two individuals. The employees received a total of 40,000 shares ...
PR Newswire · 11/09 21:15
Delcath Systems slips despite Q3 beat
Seekingalpha · 11/08 16:20
BRIEF-Delcath Systems Reports Third Quarter Results
Reuters · 11/08 15:06
Delcath Systems GAAP EPS of -$0.92, revenue of $0.9M beats by $0.09M
Seekingalpha · 11/08 14:12
Delcath Systems Q3 EPS $(0.92) Beats $(0.98) Estimate, Sales $906.00K Beat $800.00K Estimate
Benzinga · 11/08 13:04
-- Earnings Flash (DCTH) DELCATH SYSTEMS Posts Q3 Loss $-0.92
-- Earnings Flash (DCTH) DELCATH SYSTEMS Posts Q3 Loss $-0.92
MT Newswires · 11/08 08:23
More
About DCTH
Delcath Systems, Inc. is an interventional oncology company, which is focused on the treatment of primary and metastatic liver cancers. The Company's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The Company's product administers concentrated regional chemotherapy to the liver.

Webull offers kinds of Delcath Systems Inc stock information, including NASDAQ:DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.